

(2) New drug pipeline

as of June 30, 2006

| Field | Name | Development Status | Indication | Note |
|--|-----------------------------------|------------------------|--|--|
| Infusions, Clinical Nutrition & Dialysis | <i>PARESAFE</i> for i.v. infusion | Approved | Peripheral parenteral infusion with glucose, electrolyte, amino acids and vitamin B1 | Peripheral parenteral infusion with vitamin B1 in double chamber container |
| | <i>LOWHEPA</i> inj. | Approved | anticoagulant | Low molecular weight heparin in pre-filled syringe |
| | SZ-D21 | NDA filed | dialysate | Acetate-free dialysate, liquid formulation and powder formulation |
| Gastrointestinal diseases* | AJM300 | Phase II | Inflammatory bowel disease | |
| Lifestyle-related diseases** | <i>FASTIC</i> | NDA filed | Diabetes | Additional indication / Combination use with biguanide agent |
| | <i>FASTIC</i> | Phase III | Diabetes | Additional indication / Combination use with insulin-sensitising agent |
| | nateglinide † | Phase III † (Overseas) | Diabetes | Additional indication / Impaired glucose tolerance |
| | <i>ACTONEL</i> | NDA filed | Osteoporosis | Additional formulation / Once a week dosage formulation |
| | <i>ACTONEL</i> | Phase III | Paget's disease | Additional indication / Orphan drug designation |
| Other | AC-7700 (AVE-8062) ‡ | Phase I ‡ (Overseas) | Solid tumor | |

* Ajinomoto's research and development in the field of gastrointestinal diseases is centered on liver diseases and inflammatory bowel disease (IBD).

** Ajinomoto's research and development in the field of lifestyle-related diseases is centered on diabetes.

† Clinical studies are being conducted by Novartis Pharma AG (exclusive licensee outside Japan and Korea for the rights to develop, manufacture and sell the drug).

‡ Clinical studies are being conducted by Sanofi-Aventis SA (worldwide exclusive licensee for the rights to develop, manufacture and sell the drug).

(3) Newly launched products since FY 2005

as of June 30, 2006

| Field | Name | Launch | Indication or Classification | Note |
|-------------------|-------------------|-----------|--|---|
| Prescription Drug | <i>TWINPAL</i> | Oct. 2005 | Peripheral infusion with glucose, electrolyte and amino acids | Double chamber container with error proof system |
| | <i>ELENTAL</i> | Dec. 2005 | Elemental diet | Improved flavor |
| | | Dec. 2005 | Elemental diet | Improved flavor, with container (bottle) for solution |
| | <i>FASTIC</i> | May. 2006 | Diabetes | Improved (small size) 90 mg formulation |
| | <i>PNTWIN</i> | May. 2006 | Glucose, electrolyte and amino acid preparation for total parenteral nutrition | Double chamber container with error proof system |
| Medical Food | <i>MEDIF BAG</i> | July 2005 | Diet for general use | Improved formula 300mL bag, 400mL bag |
| | <i>MEDIF</i> | Oct. 2005 | Diet for general use | Improved formula 200mL package, 1000mL package |
| | <i>AQUASOLITA</i> | Mar. 2006 | Oral rehydration solution | 125 mL package |